Dr. Reckamp on Treatment Decisions in MET Exon 14–Mutated NSCLC
Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.
Karen Reckamp, MD, professor, medicine; director, Division of Medical Oncology, Cedars-Sinai Medical Center, compares capmatinib (Tabrecta) and tepotinib (Tepmetko), 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer (NSCLC).
Capmatinib and tepotinib have similar efficacy and toxicity profiles, so deciding between them should be a patient-centered choice, Reckamp says. Importantly, both agents demonstrate evidence of central nervous system activity, Reckamp notes.
Additionally, peripheral edema is the primary adverse effect of both tepotinib and capmatinib, Reckamp explains. Where these 2 drugs differ the most is in their dosing schedule: twice daily dosing is recommended for capmatinib, whereas once daily dosing is recommended for tepotinib, a schedule which may improve patient compliance with treatment.
